Quantcast

Latest Phenols Stories

2014-08-31 04:21:07

Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in the ODYSSEY LONG TERM trial TARRYTOWN, New York and PARIS, Aug. 31, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia.(...

2014-08-31 04:20:55

- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY LONG TERM trial - PARIS and TARRYTOWN, N.Y., Aug. 31, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia....

2014-08-18 12:27:28

Announces Government Action to Enhance Safe Use of Opioids OTTAWA, Aug. 18, 2014 /CNW/ - The Honourable Rona Ambrose, Minister of Health delivered a keynote address at the 147(th) Canadian Medical Association (CMA), General Council Meeting. During her remarks, the Minister affirmed the Government's commitment to continue working with the CMA on issues of importance while highlighting several themes encompassing some of her priorities, such as patient safety, prescription drug abuse, family...

2014-08-18 12:27:18

OTTAWA, Aug. 18, 2014 /CNW/ - Health Canada is advising healthcare professionals and Canadians that it has implemented labelling changes for the class of drugs known as controlled-release opioid pain medicines, to enhance their safe and appropriate use. The changes provide standardized wording that more clearly outlines the risks and safety concerns associated with controlled-release opioids. The updated guidance also encourages more appropriate patient selection and monitoring....

2014-08-16 16:21:00

OTTAWA, Aug. 16, 2014 /CNW/ - Apotex, in consultation with Health Canada, is recalling one lot (KY6601) of Apo-Mycophenolic Acid due to a package labelling error. The product is used to prevent organ rejection in patients receiving a kidney transplant. The French statement on the outer carton indicates that each tablet contains 180 mg of the medicine. The actual tablets in the package contain the correct strength of 360 mg. The rest of the carton, the leaflets, the blister...

2014-08-12 08:29:19

BEMA Buprenorphine on track for late 2014 or early 2015 NDA filing by partner Endo Pharmaceuticals RALEIGH, N.C., Aug. 12, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that along with its commercial partner, Endo Pharmaceuticals, engaged in a positive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding BEMA Buprenorphine for the management of pain severe enough to require daily, around-the-clock,...

2014-08-11 12:25:22

Postoperative "doctor shopping" linked to higher narcotic use among orthopaedic patients ROSEMONT, Ill., Aug. 11, 2014 /PRNewswire-USNewswire/ -- "Doctor shopping," the growing practice of obtaining narcotic prescriptions from multiple providers, has led to measurable increases in drug use among postoperative trauma patients. The study, "Narcotic Use and Postoperative Doctor Shopping in the Orthopaedic Trauma Population," appearing in the August issue of the Journal of Bone & Joint...

2014-08-11 08:28:23

MELBOURNE, Australia, Aug. 11, 2014 /PRNewswire/ -- -- Single dose pharmacokinetic (PK) study reproduces earlier results -- Therapeutic oxymorphone blood levels achieved in all 15 subjects -- Drug elimination indicates favourable safety profile Australian drug delivery company, Phosphagenics Limited (the Company) (ASX: POH, OTCQX: PPGNY),announces that the first of its additional studies designed to further characterise the TPM®/Oxymorphone patch, in support of an...

2014-08-07 16:29:42

BUNAVAIL(TM) (buprenorphine and naloxone) buccal film (CIII) approved by FDA for the maintenance treatment of opioid dependence; US launch planned for late Q3 RALEIGH, N.C., Aug. 7, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's recent achievements and an...

2014-08-06 20:23:58

Daiichi Sankyo and Charleston Laboratories will collaborate on development and commercialization; Charleston will supply all products and retain an option to co-promote in the United States TOKYO, PARSIPPANY, N.J. and JUPITER, Fla., Aug. 6, 2014 /PRNewswire/ -- Daiichi Sankyo and Charleston Laboratories, Inc., through its wholly owned subsidiary LOCL Pharma, Inc., announced today that the parties have entered into a strategic collaboration for the development and U.S....


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'